Lancing devices market seen reaching $4.98B by 2030

The market for lancing devices and equipment is projected to grow from $3.25 billion in 2025 to $4.98 billion by 2030, driven by rising diabetes cases, home glucose monitoring and demand for less painful sampling. North America led the market in 2025, while new report features focus on forecasting, TAM analysis and trend tracking.

Why it matters: - Lancing devices are a core tool for blood sampling, especially for diabetes management. - Rising diabetes prevalence is increasing demand for frequent, low-discomfort testing at home and in clinical settings. - The market’s projected move to $4.98 billion by 2030 signals continued growth for disposable, minimally invasive and safety-focused sampling products.

What happened: - The Business Research Company said the global lancing devices and equipment market is expected to rise from $3.25 billion in 2025 to $3.52 billion in 2026. - The company projects the market will reach $4.98 billion by 2030, implying a 9.1% CAGR over the forecast period. - The report was released Aug. 13, 2026, from London. - A free sample of the report is available here. - The full market report is available here.

The details: - Lancing devices and equipment are medical tools used to collect small blood samples, mainly for glucose testing. - The devices usually include a lancet and a mechanism that punctures the skin, often at the fingertip. - Adjustable depth settings are a common feature and help reduce discomfort during sampling. - The devices are used for routine blood glucose monitoring and other diagnostic tests that require capillary blood samples. - Growth in the past has been driven by higher diabetes rates, broader self-monitoring of blood glucose, wider access to disposable medical devices, safer lancet designs and growth in point-of-care diagnostics. - Future growth is expected to come from home diagnostics, patient comfort and adherence, chronic disease monitoring programs, minimally invasive sampling and investments in personal healthcare technologies. - Key trends include single-use safety lancets, pain-reducing sampling devices, home-based glucose monitoring, adjustable depth lancing technologies and stronger infection control measures. - North America held the largest share of the global market in 2025. - Western Europe ranked second in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The forecast points to a market shifting from basic blood sampling toward more patient-friendly and infection-conscious devices. - Home monitoring is becoming a bigger commercial opportunity as chronic disease care moves outside traditional clinical settings. - The inclusion of TAM analysis, company scoring and forecasting dashboards suggests the report is aimed at market strategists and product teams, not just clinicians. - Diabetes remains the clearest demand engine, with The Guardian reporting in February 2025 that about 12.2 million people in the U.K. were affected by diabetes or non-diabetic hyperglycaemia.

What's next: - Manufacturers are likely to keep emphasizing comfort, safety and ease of use as competition intensifies. - Further adoption of self-monitoring tools should support demand for disposable lancets and adjustable-depth devices. - Regional growth opportunities may expand beyond North America as chronic disease monitoring increases globally.

The bottom line: - Lancing devices and equipment are moving toward a larger, faster-growing market built around diabetes care, home testing and safer sampling designs.